Trastuzumab biosimilar(Curateq Biologics)

N/A

Report date: 2025/08/13 20:02:02

Base Information

Drug NameTrastuzumab biosimilar(Curateq Biologics)
Drug Alias NameBP02BP-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionImmunomodulatorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast NeoplasmsNeoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/06/30
Country/TerritoryNew ZealandBangladeshIndia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCuraTeQ Biologics Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCuraTeQ Biologics SROIQVIA RDS Pty LtdCuraTeQ Biologics Pvt Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast NeoplasmsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A